{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:07:30Z","timestamp":1761894450203},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s00417-006-0471-7","type":"journal-article","created":{"date-parts":[[2006,12,20]],"date-time":"2006-12-20T13:27:35Z","timestamp":1166621255000},"page":"941-948","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration"],"prefix":"10.1007","volume":"245","author":[{"given":"S.","family":"Aisenbrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"V\u00f6lker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gelisken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Szurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Jaissle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. U.","family":"Bartz-Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,12,21]]},"reference":[{"key":"471_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111\u2013118","journal-title":"Retina"},{"key":"471_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related degeneration. Ophthalmology 113:363\u2013372","journal-title":"Ophthalmology"},{"key":"471_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/archopht.122.4.453","volume":"122","author":"R Axel-Sieger","year":"2004","unstructured":"Axel-Sieger R, Ehrlich R, Rosenblatt I, Kramer M, Priel E, Yassur Y, Weinberger D (2004) Photodynamic therapy for occult choroidal Neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 122:453\u2013459","journal-title":"Arch Ophthalmol"},{"key":"471_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","volume":"22","author":"Eyetech Study Group","year":"2002","unstructured":"Eyetech Study Group (2002) Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143\u2013152","journal-title":"Retina"},{"key":"471_CR5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0161-6420(03)00085-X","volume":"110","author":"Eyetech Study Group","year":"2003","unstructured":"Eyetech Study Group (2003) Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110:979\u2013986","journal-title":"Ophthalmology"},{"key":"471_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581\u2013611","journal-title":"Endocr Rev"},{"key":"471_CR7","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","volume":"102","author":"FL Ferris III","year":"1984","unstructured":"Ferris FL III, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102:1640\u20131642","journal-title":"Arch Ophthalmol"},{"key":"471_CR8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182\u20131186","journal-title":"N Engl J Med"},{"key":"471_CR9","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805\u20132816","journal-title":"N Engl J Med"},{"key":"471_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher J, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"471_CR11","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1167\/iovs.02-1027","volume":"44","author":"TL Jackson","year":"2003","unstructured":"Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J (2003) Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 44:2141\u20132146","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"471_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1055\/s-2005-858231","volume":"222","author":"GB Jaissle","year":"2005","unstructured":"Jaissle GB, Szurman P, Bartz-Schmidt KU; German Retina Society; German Society of Ophthalmology; German Professional Association of Ophthalmologists (2005) Recommendation for the implementation of intravitreal injections\u2013statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 222:390\u2013395","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"471_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1517\/14728222.8.3.255","volume":"8","author":"MA Konerding","year":"2004","unstructured":"Konerding MA (2004) Ocular angiogenesis: translating preclinical indications to successful clinincal development. Expert Opin Ther Targets 8:255\u2013258","journal-title":"Expert Opin Ther Targets"},{"key":"471_CR14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","volume":"120","author":"MG Krystolik","year":"2002","unstructured":"Krystolik MG, Afshari MA, Adamis AP et al (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120:338\u2013346","journal-title":"Arch Ophthalmol"},{"key":"471_CR15","first-page":"1929","volume":"37","author":"A Kvanta","year":"1996","unstructured":"Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37:1929\u20131934","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"471_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/bjo.84.3.239","volume":"84","author":"BA Lafaut","year":"2000","unstructured":"Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, Aisenbrey S, De Laey JJ, Heimann K (2000) Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol 84:239\u2013243","journal-title":"Br J Ophthalmol"},{"key":"471_CR17","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306\u20131309","journal-title":"Science"},{"key":"471_CR18","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/archopht.1991.01080090044025","volume":"109","author":"Macular Photocoagulation Study Group","year":"1991","unstructured":"Macular Photocoagulation Study Group (1991) Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized trial. Arch Ophthalmol 109:1220\u20131241","journal-title":"Arch Ophthalmol"},{"key":"471_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","volume":"26","author":"RP Manzano","year":"2006","unstructured":"Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of Bevacizumab (Avastin). Retina 26:257\u2013261","journal-title":"Retina"},{"key":"471_CR20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA et al (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - twelve week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035\u20131047","journal-title":"Ophthalmology"},{"key":"471_CR21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/019262339902700507","volume":"27","author":"J Mordenti","year":"1999","unstructured":"Mordenti J, Cuthbertson RA, Ferrara N et al (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536\u2013544","journal-title":"Toxicol Pathol"},{"key":"471_CR22","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","volume":"89","author":"QD Nguyen","year":"2005","unstructured":"Nguyen QD, Shah S, Tatlipinar S et al (2005) Bevacizumab suppresses choroidal neovascularization cased by pathological myopia. Br J Ophthalmol 89:1368\u20131370","journal-title":"Br J Ophthalmol"},{"key":"471_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/00006982-200512000-00016","volume":"25","author":"D Pauleikhoff","year":"2005","unstructured":"Pauleikhoff D (2005) Neovascular age-related macular degeneration. Natural history and treatment outcomes. Retina 25:1065\u20131084","journal-title":"Retina"},{"key":"471_CR24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3928\/1542-8877-20050701-03","volume":"36","author":"E Reichel","year":"2005","unstructured":"Reichel E (2005) Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment? Ophthalmic Surg Lasers Imaging 36:270\u2013271","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"471_CR25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Mosfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331\u2013335","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"471_CR26","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","volume":"112","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048\u20131053","journal-title":"Ophthalmology"},{"key":"471_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/jcp.10246","volume":"195","author":"Y Saishin","year":"2003","unstructured":"Saishin Y, Saichin Y, Tkahashi K et al (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241\u2013248","journal-title":"J Cell Physiol"},{"key":"471_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A (2006) Electrophysiological and retinal penetration studies following intravitreal injection of Bevacizumab (Avastin). Retina 26:262\u2013269","journal-title":"Retina"},{"key":"471_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00006982-200604000-00001","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383\u2013390","journal-title":"Retina"},{"key":"471_CR30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","author":"Treatment of age-related macular degeneration with photodynamic therapy study group","year":"1999","unstructured":"Treatment of age-related macular degeneration with photodynamic therapy study group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 117:1329\u20131345","journal-title":"Arch Ophthalmol"},{"key":"471_CR31","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/archopht.121.9.1253","volume":"121","author":"Treatment of age-related macular degeneration with photodynamic therapy study group, Verteporfin in Photodynamic Therapy Study Group","year":"2003","unstructured":"Treatment of age-related macular degeneration with photodynamic therapy study group, Verteporfin in Photodynamic Therapy Study Group (2003) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report No. 2. Arch Ophthalmol 121:1253\u20131268","journal-title":"Arch Ophthalmol"},{"key":"471_CR32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/00006982-200510000-00001","volume":"25","author":"VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group","year":"2005","unstructured":"VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group (2005) Enhanced efficacy associated with early treatment of neovascular macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 25:815\u2013827","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-006-0471-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-006-0471-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-006-0471-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-006-0471-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T02:20:38Z","timestamp":1652581238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-006-0471-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1007\/s00417-006-0471-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"29 March 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}